An 8th paper has been retracted for Anna Ahimastos, a heart researcher who faked patient records.
It’s the last in a chain of retractions that were the result of an investigation by her former workplace, Baker IDI Heart & Diabetes Institute in Australia. As with the others, she did not agree to the retraction.
The investigation found fabricated patients records in some papers; in other papers, such as the newly retracted 2010 study in Atherosclerosis, the original data source could not be verified. The latest retraction — “A role for plasma transforming growth factor-β and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?” — followed up on a previous clinical trial, examining how a blood pressure drug might help patients with a life-threatening genetic disorder.
That previous trial — which also included 17 patients with Marfan syndrome treated with either placebo or perindopril — has been retracted from JAMA; the New England Journal of Medicine has also retracted a related letter.
The latest retraction note conveys similar information to the other perindopril/Marfan syndrome retractions: Continue reading 8th retraction appears for researcher who faked patient records
Anna Ahimastos, a heart researcher who faked patient records, has notched her 7th retraction.
One more paper is expected to be retracted, according to a spokesperson from her former institution, the Baker IDI Heart & Diabetes Institute in Australia.
As with the other retractions, the 2005 paper in Hypertension — about how the hypertension drug ramipril may help alleviate cardiovascular disease — is being pulled after Ahimastos admitted to scientific misconduct. She asserts the data remain valid, and has not signed the retraction notice.
The Hypertension paper has been cited 63 times, according to Thomson Scientific’s Web of Knowledge. Here’s the retraction note in full (the language will be familiar to readers who have been following this case):
Continue reading 7th retraction for heart researcher who faked patient records
A heart researcher who fabricated patient records has notched retraction number six — this time, for a letter in the New England Journal of Medicine. She has two more retractions forthcoming.
The retraction comes at the request of Anna Ahimastos’s co-authors, following an investigation into her work by her former workplace, the Baker IDI Heart and Diabetes Institute. The investigation was not able to verify the data referenced in the letter, which includes a citation for a recently retracted JAMA paper.
The retraction note is similar to others for Ahimastos’s papers:
Continue reading NEJM pulls letter by heart researcher who faked patient records
A heart researcher who fabricated trial participants has notched a second JAMA retraction. The retraction comes at the request of her co-authors, after an investigation by her former employer wasn’t able to confirm that this study was valid.
In September, we learned that Anna Ahimastos, who used to work at Baker IDI Heart and Diabetes Institute in Melbourne, Australia, had “fabricated [records] for trial participants that did not exist” in a JAMA trial for a blood pressure drug, according to principal investigator Bronwyn Kingwell. That trial was retracted, along with a sub analysis.
An investigation by the institute found problems or sufficient doubt in several more publications. This second JAMA retraction is number 5 for Ahimastos, of 8 total expected.
The paper, “Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial” Continue reading JAMA retracts second paper by heart researcher
A heart researcher who fabricated patient records for her studies on the blood pressure medication ramipril has earned her fourth retraction, and more are apparently on the way.
For readers who are new to this case: Things first unraveled for Anna Ahimastos when a subanalysis of a JAMA clinical trial revealed “anomalies,” triggering an investigation. After Ahimastos admitted to fabricating patient data, that JAMA paper and two others — including a small trial in Annals of Internal Medicine — were pulled. A spokesperson for her former employer, Baker IDI Heart & Diabetes Institute, told us last week that they have requested more retractions:
Five papers and one letter are in the process of being retracted.
The Annals and this latest paper are included in the five papers, so we expect to see Continue reading Heart researcher who faked patient data gets 4th retraction
A heart researcher has notched her third retraction, a small 2006 trial in Annals of Internal Medicine which seemed to show that a blood pressure drug could help people with artery disease walk further with less pain.
Earlier this year, Anna Ahimastos, formerly a researcher at Baker IDI Heart and Diabetes Institute in Melbourne, lost a larger clinical trial in JAMA and a subanalysis in Circulation Research after it was discovered she’d fabricated patient records. As principle investigator Bronwyn Kingwell told us in September:
Specifically, records were fabricated for trial participants that did not exist.
Now, following an investigation by the institute, her co-authors are proactively retracting papers, with more to come. The Annals of Internal Medicine paper, “Ramipril Markedly Improves Walking Ability in Patients With Peripheral Arterial Disease,” is being pulled due to an “inability to adequately validate primary data sources.” According to the note, Ahimastos “maintains the integrity of the data and validity of reported results:”
Continue reading Heart researcher who faked patient data gets third retraction
A JAMA clinical trial that suggested a blood pressure drug could help patients increase their physical fitness, and a sub-analysis of those data, have been retracted after “an admission of fabricated results” by the first author on both papers.
The three-year clinical trial was published in JAMA in 2013. It was retracted this morning.
The trial found ramipril helped patients with artery disease walk longer and with less pain, according to the abstract:
Among patients with intermittent claudication, 24-week treatment with ramipril resulted in significant increases in pain-free and maximum treadmill walking times compared with placebo. This was associated with a significant increase in the physical functioning component of the SF-36 score.
The retraction note explains how the fabricated data came to light:
Continue reading “Fabricated results” retract JAMA clinical trial, plus a sub-analysis of the data